Retrospective Analysis of the Use of Tiludronate in Equine Practice: Safety on 1804 Horses, Efficacy on 343 Horses.

The objective of this retrospective study was to assess the safety and efficacy of a slow IV administration of 1mg/kg tiludronate in a large number of horses. Each horse that received at least one tiludronate-based treatment between 2006 and August 2019 at Virginia Equine Imaging or Fairfield Equine was included in the study. Concomitant medical treatments, preliminary nonsteroidal anti-inflammatory drug injection and potential side effects were recorded after each administration. Horses for which follow-up was available over 1 year were subject to clinical evolution assessment via lameness grade evolution and performance data when available. Collected data suggest excellent tolerance to tiludronate with only 0.9% of the 2,497 injections (1,804 horses) inducing potential side effects, mild colics being the most frequent. Clinical follow-up was available over more than 1 year for 343 horses. Most horses (>80%) presented an initial lameness score over 1.5/5, approximately half of the population was sound by 30 days and remained so after a year. Mean lameness score improved by more than one grade during the follow-up period compared to initial examination. Performance data were available for 129 horses. One year after treatment, 89 (69%) horses were still competing, 73 (82%) of them at a better or similar level. These data suggest good efficacy of tiludronate over a year after treatment. Despite limitations inherent to any field study, this is the first retrospective study of the use of bisphosphonates in horses combining a large group with long-term follow-ups.

Owners' perception of the efficacy of Newmarket bloodroot ointment in treating equine sarcoids.

A retrospective questionnaire-based survey was used to determine the perceived efficacy of Newmarket bloodroot ointment in treating equine sarcoids. In 49 horses with 74 sarcoids, 64 sarcoids responded either completely (n = 49) or partially (n = 15) while 10 did not respond or worsened. Sarcoids < 2 cm responded better to treatment (P < 0.001) than did larger sarcoids.

Perception des propriétaires sur l'efficacité de l'onguent à la sanguinaire de Newmarket pour traiter les sarcoïdes équines. Un sondage rétrospectif réalisé par questionnaire a été utilisé pour déterminer l'efficacité perçue de l'onguent à la sanguinaire de Newmarket pour traiter les sarcoïdes équines. Chez 49 chevaux atteints de 74 sarcoïdes, 64 sarcoïdes ont soit répondu complètement (n = 49) ou partiellement (n = 15) tandis que 10 n'ont pas répondu ou se sont aggravées. Les sarcoïdes de < 2 cm ont mieux répondu au traitement (P < 0,001) que les sarcoïdes plus grandes.(Traduit par Isabelle Vallières).